References
1 Xia Shuai, Wang Lijue, Zhu Yun, Lu Lu, Jiang Shibo. Origin,
virological features, immune evasion and intervention of SARS-CoV-2
Omicron sublineages. Signal Transduct Target Ther2022;7 (1):1–7. Doi: 10.1038/s41392-022-01105-9.
2 COVID-19 Weekly Epidemiological Update 135. World Health
Organization, 2023.
3 Doll Margaret K., Waghmare Alpana, Heit Antje, Levenson Shakoor
Brianna, Kimball Louise E., Ozbek Nina, et al. Acute and Postacute
COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs
Omicron Waves. JAMA Netw Open 2023;6 (2):e231181. Doi:
10.1001/jamanetworkopen.2023.1181.
4 Looi Mun Keat. How are covid-19 symptoms changing? BMJ2023;380 :p3. Doi: 10.1136/bmj.p3.
5 Bahremand Taraneh, Yao Jiayun Angela, Mill Christopher, Piszczek
Jolanta, Grant Jennifer M., Smolina Kate. COVID-19 hospitalisations in
immunocompromised individuals in the Omicron era: a population-based
observational study using surveillance data in British Columbia, Canada.Lancet Reg Heal - Am 2023;20 (100461):1–8. Doi:
10.1016/j.lana.2023.100461.
6 Hyams Catherine, Challen Robert, Marlow Robin, Nguyen Jennifer, Begier
Elizabeth, Southern Jo, et al. Severity of Omicron (B.1.1.529) and Delta
(B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A
prospective cohort study in Bristol, United Kingdom. Lancet Reg
Heal - Eur 2023;25 :1–11. Doi: 10.1016/j.lanepe.2022.100556.
7 Pulliam Juliet R.C., van Schalkwyk Cari, Govender Nevashan, von
Gottberg Anne, Cohen Cheryl, Groome Michelle J., et al. Increased risk
of SARS-CoV-2 reinfection associated with emergence of Omicron in South
Africa. Science (80- ) 2022;376 (6593):1–8. Doi:
10.1126/science.abn4947.
8 Goga Ameena, Bekker Linda Gail, Garrett Nigel, Reddy Tarylee,
Yende-Zuma Nonhlanhla, Fairall Lara, et al. Breakthrough SARS-CoV-2
infections during periods of delta and omicron predominance, South
Africa. Lancet 2022;400 (10348):269–71. Doi:
10.1016/S0140-6736(22)01190-4.
9 Magazine Nicholas, Zhang Tianyi, Wu Yingying, McGee Michael C.,
Veggiani Gianluca, Huang Weishan. Mutations and Evolution of the
SARS‐CoV‐2 Spike Protein. Viruses 2022;14 (3):1–11. Doi:
10.3390/v14030640.
10 Carabelli Alessandro M., Peacock Thomas P., Thorne Lucy G., Harvey
William T., Hughes Joseph, de Silva Thushan I., et al. SARS-CoV-2
variant biology: immune escape, transmission and fitness. Nat Rev
Microbiol 2023;21 :162–77. Doi: 10.1038/s41579-022-00841-7.
11 Mahase Elisabeth. Covid-19: What do we know about XBB.1.5 and should
we be worried? BMJ 2023;380 (p153):1–2. Doi:
10.1136/bmj.p153.
12 Faas Michel R, Mak Willem A, Markus Hilde Y, Zwan Ellen M Van Der,
Vliet Marijke Van Der, Koeleman Johannes G M, et al. Dynamics of
Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and
the Impact of Booster Vaccinations in Previously Infected and
Infection-Naïve Individuals. Vaccines 2022;10 (2132).
13 Mak Willem A., Koeleman Johannes G.M., van der Vliet Marijke, Keuren
Frans, Ong David S.Y. SARS-CoV-2 antibody and T cell responses one year
after COVID-19 and the booster effect of vaccination: A prospective
cohort study. J Infect 2022;84 (2):171–8. Doi:
10.1016/j.jinf.2021.12.003.
14 Mak Willem A, Koeleman Johannes G M, Ong David S Y. Development of an
in-house SARS-CoV-2 interferon-gamma ELISpot and plate reader-free spot
detection method. J Virol Methods 2022;300 (114398):1–6.
Doi: 10.1016/j.jviromet.2021.114398.
15 Ong David S.Y., Keuren Frans, van der Vliet Marijke, Boxma – de
Klerk Bianca M., Koeleman Johannes G.M. SARS-CoV-2 antibody response
dynamics and heterogeneous diagnostic performance of four serological
tests and a neutralization test in symptomatic healthcare workers with
non-severe COVID-19. J Clin Virol 2021;141 (104904):1–3.
Doi: 10.1016/j.jcv.2021.104904.
16 Barouch Dan H. Covid-19 Vaccines — Immunity, Variants, Boosters.N Engl J Med 2022;387 (11):1011–20. Doi:
10.1056/nejmra2206573.
17 Takeuchi Junko S, Fukunaga Ami, Yamamoto Shohei, Tanaka Akihito,
Matsuda Kouki, Kimura Moto, et al. SARS‑CoV‑2 specific T cell and
humoral immune responses upon vaccination with BNT162b2: a 9 months
longitudinal study. Sci Rep 2022;12 (15447):1–9. Doi:
10.1038/s41598-022-19581-y.
18 Terpos Evangelos, Karalis Vangelis, Ntanasis-Stathopoulos Ioannis,
Apostolakou Filia, Gumeni Sentiljana, Gavriatopoulou Maria, et al.
Sustained but Declining Humoral Immunity against SARS-CoV-2 at 9 Months
Postvaccination with BNT162b2: A Prospective Evaluation in 309 Healthy
Individuals. HemaSphere 2022;6 (1):E677. Doi:
10.1097/HS9.0000000000000677.
19 Dieckhaus Kevin D., Kim Min Jung, Shen Jian Bing, Liang Tina S.,
Kleinberg Michael J., Siedlarz Kristen M., et al. SARS-CoV-2 Antibody
Dynamics in Healthcare Workers after mRNA Vaccination. Vaccines2023;11 (2). Doi: 10.3390/vaccines11020358.
20 COVID-19 Forecasting Team. Past SARS-CoV-2 Infection Protection
Against Reinfection: A Systematic Review and Meta-Analysis.Lancet 2023;6736 (22):1–11. Doi:
10.1016/S0140-6736(22)02465-5.
21 Tuekprakhon Aekkachai, Nutalai Rungtiwa, Dijokaite-Guraliuc Aiste,
Zhou Daming, Ginn Helen M., Selvaraj Muneeswaran, et al. Antibody escape
of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.Cell 2022;185 (14):2422-2433.e13. Doi:
10.1016/j.cell.2022.06.005.
22 Lyke Kirsten E., Atmar Robert L., Islas Clara Dominguez, Posavad
Christine M., Szydlo Daniel, Paul Chourdhury Rahul, et al. Rapid decline
in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron
variant. Cell Reports Med 2022;3 (7). Doi:
10.1016/j.xcrm.2022.100679.
23 Keeton Roanne, Tincho Marius B., Suzuki Akiko, Benede Ntombi, Ngomti
Amkele, Baguma Richard, et al. Impact of SARS-CoV-2 exposure history on
the T cell and IgG response. Cell Reports Med2023;4 (1):100898. Doi: 10.1016/j.xcrm.2022.100898.
24 Almendro-Vázquez Patricia, Chivite-Lacaba Marta, Utrero-Rico Alberto,
González-Cuadrado Cecilia, Laguna-Goya Rocio, Moreno-Batanero Miguel, et
al. Cellular and humoral immune responses and breakthrough infections
after three SARS-CoV-2 mRNA vaccine doses. Front Immunol2022;13 (981350):1–11. Doi: 10.3389/fimmu.2022.981350.
25 Lozano-Ojalvo Daniel, Camara Carmen, Lopez-Granados Eduardo, Nozal
Pilar, del Pino-Molina Lucía, Bravo-Gallego Luz Yadira, et al.
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T
cell immunity in naive and COVID-19 recovered individuals. Cell
Rep 2021;36 (109570):1–5. Doi: 10.1016/j.celrep.2021.109570.
26 Kundu Rhia, Narean Janakan Sam, Wang Lulu, Fenn Joseph, Pillay
Timesh, Fernandez Nieves Derqui, et al. Cross-reactive memory T cells
associate with protection against SARS-CoV-2 infection in COVID-19
contacts. Nat Commun 2022;13 (1):1–8. Doi:
10.1038/s41467-021-27674-x.
27 Wolter Nicole, Jassat Waasila, Walaza Sibongile, Welch Richard,
Moultrie Harry, Groome Michelle J., et al. Clinical severity of
SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in
South Africa. Nat Commun 2022;13 (1):1–8. Doi:
10.1038/s41467-022-33614-0.
28 Swadling Leo, Maini Mala K. T cells in COVID-19 — united in
diversity. Nat Immunol 2020;21 (11):1307–8. Doi:
10.1038/s41590-020-0798-y.
29 GeurtsvanKessel Corine H., Geers Daryl, Schmitz Katharina S., Mykytyn
Anna Z., Lamers Mart M., Bogers Susanne, et al. Divergent SARS-CoV-2
Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.Sci Immunol 2022;7 (69):1–12. Doi:
10.1126/sciimmunol.abo2202.
30 Jacobsen Henning, Cobos Jiménez Viviana, Sitaras Ioannis, Bar-Zeev
Naor, Čičin-Šain Luka, Higdon Melissa M., et al. Post-vaccination T cell
immunity to omicron. Front Immunol 2022;13 (944713):1–8.
Doi: 10.3389/fimmu.2022.944713.
31 Park Kyemyung, Choi Seung Jin, Shin Eui Cheol. Omicron Subvariants,
Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of
Ancestral SARS-CoV-2. Immune Netw 2022;22 (4):8–10. Doi:
10.4110/in.2022.22.e29.
32 Choi Seong Jin, Kim Dong Uk, Noh Ji Yun, Kim Sangwoo, Park Su Hyung,
Jeong Hye Won, et al. T cell epitopes in SARS-CoV-2 proteins are
substantially conserved in the Omicron variant. Cell Mol Immunol2022;19 (3):447–8. Doi: 10.1038/s41423-022-00838-5.
33 COVID-19 weekly epidemiological update 123. World Health
Organization , 2022.